mProX™ Human PIM3 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1222-KX436	Magic™ Human PIM3 in Vitro Assay	Human		Kinase Assay

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;HuH-6

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Hepatic Flexure Cancer; Spinocerebellar Ataxia, X-Linked 5

Gene ID

Human:415116

UniProt ID

Human:Q86V86

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

PIM3, a member of the PIM kinase family, has been identified as a crucial player in various cellular processes, including cell survival, proliferation, and differentiation. In the realm of scientific research, PIM3 has garnered attention for its role in tumorigenesis and cancer progression. Specifically, PIM3 has been implicated in the development and progression of hepatocellular carcinoma (HCC), a prevalent and aggressive form of liver cancer. The kinase has been found to promote the survival of HCC cells, making it a potential therapeutic target for the treatment of this malignancy. Furthermore, the overexpression of PIM3 has been associated with poor prognosis in patients with pancreatic ductal adenocarcinoma, suggesting its potential as a prognostic biomarker. The significance of PIM3 in cancer biology underscores the need for further research to elucidate its molecular mechanisms and therapeutic potential.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human PIM3 Stable Cell Line (S01YF-1023-PY57). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Casey Davis (Verified Customer)

How does PIM3 influence bladder cancer progression? Feb 17 2021

chat Patrick Liam (Creative Biolabs Scientific Support)

PIM3, modulated by the LINC01232/miR-370-5p axis, promotes cell proliferation, migration, and invasion in bladder cancer. Feb 17 2021

chat Taylor Smith (Verified Customer)

What is the role of PIM3 in gastric cancer? Mar 23 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

The FALEC/miR-203b/PIM3 axis induces malignant behaviors in gastric cancer cells, suggesting a potential therapeutic target. Mar 23 2023

Published Data

Fig.1 The anti-proliferation phenotype that had been observed with siRNA knockdown was mitigated by the overexpression of PIM3.

SiNeg or siPIM3 were transfected into HuH6 cells, followed by transfection with a PIM3 overexpression vector or an empty vector (ev). (Upper panel) Reduced PIM3 expression in siPIM3-transfected cells and elevated PIM3 expression in cells transfected with the PIM3 overexpression vector were confirmed by immunoblotting. (Lower panel) Diminished proliferation was observed in cells transfected with siPIM3 followed by ev, as previously noted. However, when PIM3 overexpression was introduced into cells with PIM3 knocked down, the proliferation level was restored to baseline.

Ref: Stafman, Laura L., et al. "The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival." Journal of pediatric surgery 54.6 (2019): 1206-1213.

Pubmed: 30898394

DOI: 10.1016/j.jpedsurg.2019.02.029

Research Highlights

Huang, Haixin. et al. "Effect of intravenous immunoglobulin on the outcome of children with septic shock in a PICU: a retrospective cohort study." European journal of pediatrics, 2023.
The efficacy of administering intravenous immunoglobulin (IVIG) on children with septic shock remains uncertain. A retrospective study was conducted at a tertiary pediatric hospital to investigate the impact of IVIG treatment in the pediatric intensive care unit (PICU). The data of 304 children admitted to the PICU for septic shock from January 2017 to December 2021 were analyzed. The main outcome, in-hospital mortality, showed no significant difference between the group that received IVIG and the group that did not. However, those who received IVIG required more continuous renal replacement therapy, longer duration of mechanical ventilation, and longer length of stay in the PICU and the hospital. Survival analysis at 28 days showed better survival rates in the IVIG group, although there was no significant difference in in-hospital mortality. Propensity score matching and inverse probability weighting analyses also showed no significant difference in mortality between the groups.
Huang, Haixin. et al. "Effect of intravenous immunoglobulin on the outcome of children with septic shock in a PICU: a retrospective cohort study." European journal of pediatrics, 2023.
Pubmed: 37733114 DOI: 10.1007/s00431-023-05224-5

Zhao, Xin et al. "PIM3-AMPK-HDAC4/5 axis restricts MuERVL-marked 2-cell-like state in embryonic stem cells." Stem cell reports vol. 17,10 (2022): 2256-2271.
In this study, researchers have delved into the mechanisms that regulate the suppression of the MuERVL-associated 2-cell-like state in embryonic stem cells (ESCs). They have identified the PIM3-downstream signaling axis as a critical pathway responsible for repressing MuERVL and maintaining ESCs in their pluripotent state. When PIM3 is downregulated, deleted, or inhibited, it leads to the activation of MuERVL, 2-cell genes, and trophectodermal genes in ESCs. Through their investigation, they have pinpointed AMPK as a key target of PIM3 regulation, and the loss of PIM3 results in increased AMPK phosphorylation. This, in turn, phosphorylates HDAC4/5, causing their relocation from the nucleus, ultimately resulting in the activation of MuERVL and the 2-cell-like state. In summary, this research uncovers a previously unknown pathway in which PIM3 acts to suppress the 2-cell marker MuERVL and the totipotent state in ESCs.
Zhao, Xin et al. "PIM3-AMPK-HDAC4/5 axis restricts MuERVL-marked 2-cell-like state in embryonic stem cells." Stem cell reports vol. 17,10 (2022): 2256-2271.
Pubmed: 36150380 DOI: 10.1016/j.stemcr.2022.08.009